Publications by authors named "Peter End"

Claim this Profile
N
Novel Bruton's tyrosine kinase inhibitor remibrutinib: Assessment of drug-drug interaction potential as a perpetrator of cytochrome P450 enzymes and drug transporters and the impact of covalent binding on possible drug interactions.
Hilmar Schiller, Felix Huth, Carole Schuhler, Anton Drollmann, Martin Kaul, Wendy Weis, Peter End

Eur J Pharm Sci· May 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
N
Novel Bruton's Tyrosine Kinase inhibitor remibrutinib: Drug-drug interaction potential as a victim of CYP3A4 inhibitors based on clinical data and PBPK modeling.
Felix Huth, Hilmar Schiller, Yi Jin, Birk Poller, Carole Schuhler, Wendy Weis, Peter End

Clin Transl Sci· January 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A Unidirectional 96-Well Fluidic Culture Platform for Upstream Cell Dosing with Subsequent Downstream Nonlinear and Ascending Exposure Gradients for Real-Time and Cell-Based Toxicity Screening Environments.
Bincy A John, David J Sloan, Timothy C Jensen, Sreenivasa C Ramaiahgari, Peter End

Appl In Vitro Toxicol· December 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Remibrutinib (LOU064): A selective potent oral BTK inhibitor with promising clinical safety and pharmacodynamics in a randomized phase I trial.
Martin Kaul, Peter End, Maciej Cabanski, Carole Schuhler, Annamaria Jakab

Clin Transl Sci· September 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Addition of iptacopan, an oral factor B inhibitor, to eculizumab in patients with paroxysmal nocturnal haemoglobinuria and active haemolysis: an open-label, single-arm, phase 2, proof-of-concept trial.
Antonio M Risitano, Alexander Röth, Juliette Soret, Camilla Frieri, Flore Sicre de Fontbrune, Peter End

Lancet Haematol· May 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
N
New Perspectives on Drug-Induced Liver Injury Risk Assessment of Acyl Glucuronides.
Markus Walles, Alan P Brown, Alfred Zimmerlin, Peter End

Chem Res Toxicol· July 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
F
Fevipiprant has a low risk of influencing co-medication pharmacokinetics: Impact on simvastatin and rosuvastatin in different SLCO1B1 genotypes.
Birk Poller, Ralph Woessner, Avantika Barve, Hanns-Christian Tillmann, Janardhana Vemula, Peter End

Pulm Pharmacol Ther· August 2019

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Absorption, Distribution, Metabolism, and Excretion of the Oral Prostaglandin D2 Receptor 2 Antagonist Fevipiprant (QAW039) in Healthy Volunteers and In Vitro.
David Pearson, H Markus Weiss, Yi Jin, Jan Jaap van Lier, Veit J Erpenbeck, Peter End

Drug Metab Dispos· July 2017

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Drug-induced liver injury: recent advances in diagnosis and risk assessment.
Gerd A Kullak-Ublick, Raul J Andrade, Michael Merz, Peter End, Andreas Benesic

Gut· June 2017

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
H
High-Throughput Melanin-Binding Affinity and In Silico Methods to Aid in the Prediction of Drug Exposure in Ocular Tissue.
John Reilly, Sarah L Williams, Cornelia J Forster, Viral Kansara, Peter End

J Pharm Sci· December 2015

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Discovery of BAF312 (Siponimod), a Potent and Selective S1P Receptor Modulator.
Shifeng Pan, Nathanael S Gray, Wenqi Gao, Yuan Mi, Yi Fan, Peter End

ACS Med Chem Lett· March 2013

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
U
Urinary clusterin, cystatin C, beta2-microglobulin and total protein as markers to detect drug-induced kidney injury.
Frank Dieterle, Elias Perentes, André Cordier, Daniel R Roth, Pablo Verdes, Peter End

Nat Biotechnol· May 2010

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Absorption, distribution, metabolism, and elimination of the direct renin inhibitor aliskiren in healthy volunteers.
Felix Waldmeier, Ulrike Glaenzel, Bernard Wirz, Lukas Oberer, Dietmar Schmid, Peter End

Drug Metab Dispos· August 2007

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis